Kamile Kırca, Sevinç Kutlutürkan, Kıymet Akgedik, Firdevs Doğanay

Paklitaksel uygulanan hastalarda hipersensitivite reaksiyonları: Üç olgu sunumu

Hipersensitivite reaksiyonları, antineoplastik ilaç uygulamalarında ortaya çıkan acil müdahale gerektiren durumlardır. Akciğer, meme ve over kanseri gibi malign hastalıklarda kür, kontrol ve palyasyon amacıyla uygulanan paklitaksel, hastalarda %8-45 oranında hiperpensitivite reaksiyonuna neden olmaktadır. Dispne, ürtiker, hipotansiyon, eritem, göğüs ve sırt ağrısı bu hastaların hipersensitivite ile ilişkili başlıca yakınmalarıdır. Onkoloji hemşirelerinin, kemoterapi ile ilişkili hipersensitivite reaksiyonlarının önlenmesi, kontrolü ve yönetiminde önemli sorumlulukları vardır. Olgu sunumlarımız, paklitaksel uygulanan hastalarda gelişen hipersensitivite reaksiyonları ve hemşirelik girişimleri ele alınarak tartışılmıştır.

Anahtar Kelimeler:

Hipersensitivite reaksiyonu, paklitaksel, hemşirelik bakımı

PDF

___

1. Gerper RV. Chemotherapy and Biotherapy- Induced Hypersensitivity Reactions. J Infus Nurs 2009; 32(3):157-165
2. Ruggiero A et al. Incidence, Clinical Features and Management of Hypersensitivity Reactions to Chemotheropeutic Drugs in children with Cancer. Eur J Clin Pharmacol 2013; 69: 1739-1746.
3. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4. 03. Published date June 14, 2010. http://evs. nci. nih. gov/ft p1/CTCAE/CTCAE_4. 03_2010-06-14_QuickReference_5x7.pdf (Erişim tarihi: 05.02.2016)
4. Özcan K, Tuna İ, Yılmaz K, Zorlu R, Mollaoğlu M, Şen F. Hipersensitivite reaksiyonları. Can G (editör). Onkoloji hemşireliğinde kanıttan Uygulamaya-Konsensus2014.2015; 53-61
5. Guidelines for Management of Intravenous Systemic Anti- Cancer Therapy Related Hypersensitivity Reactions including Anaphylaxis http://www.londoncancer.org/media/79795/London-Cancer-Chemo-Hypersensitivity-Guideline-v1-FINAL-VERSION.pdf (2015) Erişim tarihi: 02.25.2016
6. Makrilia N, Syrigou E, Kaklamonos I, et al. Hipersensitiviy Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review. Met Based Drugs 2010;1-11.
7. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology.Ann Oncol 2012; 23(10): 313-9.
8. Vogel WH. Infusion Reactions: Diagnosis, Assessment and Management. Clin J Oncol Nurs. 2010;14(2):E10-12
9. Muallaoğlu S, Disel U, Mertsoylu H, Besen A, Karadeniz C, Sumbul TA, Abali HA, Ozyilkan O. Acute infusion reactions to chemotherapeutic drugs: a single institute experience. J BUON 2013; 18(1): 261-267
10. Banerji A, Lax T, Guyer A, Hurwitz S, Camargo CA Jr, Long AA. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2014;2(4):428-33.
11. Henry A, Charpiat B, Perol M, Vial T, de Saint Hilaire PJ, Descotes J. Paclitaxel Hypersensitivity Reactions: Assessment of the Utility of a Test-Dose Program. Cancer J 2006; 12 (3):237-245
12. Lal SL, Gerber LD, Lau J, Dana W. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center. Support Care Cancer 2009 ;17(10):1311–1315
13. Yahata H, Saito M, Sendo T, Itoh Y, Uchida M, Hirakawa T, Nakano H, Oishi R. Prophylactic effect of pemurolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int.J.Cancer 2006;118(10): 2636-2638
14. Tham EH, Cheng YK, Tay MH, Alcasabas AP, Shek LP. Evaluation and management of hypersensitivity reactions to chemotherapy agents. 2015; 91(1073): 145-50.
15. Breslin, S. Cytokine-release syndrome: Overview and nursing implications. Clin J Oncol Nurs 2007; 11(1, Suppl.): 37–42.
16. Gobel, B.H. Chemotherapy-induced hypersensitivity reactions. Oncology Nursing Forum 2005; 32(5): 1027–1035
17. Kang, S.P., Saif, M.W. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer—Identification, prevention, and management. Journal of Supportive Oncology, 2007;5(9):451–457.